Orexigen's Date With Destiny

This week, Orexigen's (NASDAQ: OREX  ) obesity drug, Contrave, is up for Food and Drug Administration approval.


The biotech originally tried to gain approval for Contrave a few years ago, but the FDA rejected the drug, asking for a clinical trial to ensure there weren't heart problems. Orexigen ran the trial, and the interim data ruled out an increase in heart problems above a certain threshold. At this point, an approval seems likely.

It remains to be seen whether Contrave will be able to succeed where Arena Pharmaceuticals' (NASDAQ: ARNA  ) Belviq and VIVUS's  (NASDAQ: VVUS  ) Qsymia have struggled. Contrave has better efficacy Belviq and a better safety profile than Qsymia. Unfortunately, with the heart trial still ongoing, the interim data isn't expected to be on the label.

Watch the video below to see what senior biotech specialist Brian Orelli and health-care analyst David Williamson think of the competition between Orexigen, Arena Pharmaceuticals, and VIVUS.

Multi-bagger potential, no binary event required
Give us five minutes and we'll show how you could own the best stock for 2014. Every year, The Motley Fool's chief investment officer hand-picks one stock with outstanding potential. But it's not just any run-of-the-mill company. It's a stock perfectly positioned to cash in on one of the upcoming year's most lucrative trends. Last year his pick skyrocketed 134%. And previous top picks have gained upwards of 908%, 1,252% and 1,303% over the subsequent years! Believe me, you don't want to miss what could be his biggest winner yet! Just click here to download your free copy of "The Motley Fool's Top Stock for 2014" today.

Read/Post Comments (2) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On June 11, 2014, at 1:29 AM, marp11 wrote:


    2 generics no money

    see vvus

    watch belviq pre diabetes presentation saturday

    then see nbc news last night

  • Report this Comment On June 11, 2014, at 8:33 AM, marp11 wrote:



Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2989061, ~/Articles/ArticleHandler.aspx, 9/4/2015 6:28:37 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Brian Orelli

Dr. Orelli is a Senior Biotech Specialist. He has written about biotech, pharmaceutical, and medical device companies for The Motley Fool since 2007.

Today's Market

updated 9 hours ago Sponsored by:
DOW 16,374.76 23.38 0.14%
S&P 500 1,951.13 2.27 0.12%
NASD 4,733.50 -16.48 -0.35%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/3/2015 3:59 PM
OREX $2.75 Up +0.01 +0.18%
Orexigen Therapeut… CAPS Rating: **
ARNA $2.75 Up +0.05 +1.85%
Arena Pharmaceutic… CAPS Rating: **
VVUS $1.26 Up +0.02 +1.61%
VIVUS, Inc. CAPS Rating: **